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The gap between researchers and
patients, eager to move on with
research on therapeutic
embryonic stem-cell cloning, and
regulators and opponents keen to
keep a grip on or prevent
developments shows little sign of
receding.
In the UK, which was one of the
first countries to legislate licenses
for research on early human
embryos, the country’s highest
court last month said it will allow
an anti-abortion group to appeal
an earlier defeat that opened the
door to such human therapeutic
cloning research.
Last November, the High Court
ruled that the Human Fertilization
and Embryology Act, passed in
1990 before human cloning
seemed possible, applied only to
embryos created by fusion of egg
and sperm – and not those made
by cloning techniques. But after
an appeal court overturned that
ruling, the House of Lords gave
the go-ahead to a government
panel to issue licenses for
therapeutic cloning research. Now
the Judicial Office of the House of
Lords has ruled that the anti-
embryo research group ProLife
Alliance can challenge the current
regulatory system. The case is
expected to be heard later this
year. A judgement in favour of the
challenge could have a serious
effect on Britain’s stem cell
research.
In the US, researchers are still
waiting to get a full bite of the
research apple in the face of a
public funding ban on most
aspects of such research. But
there is now a small hope that a
ban may turn into a moratorium
with the prospect eventually of
some research. The
US President’s Council on
Bioethics, which advises
President Bush on issues in
medicine and biology, appears to
be edging towards that
recommendation. At its meeting in
Washington DC last month, all of
the council’s members supported
a ban on cloning to produce a
human baby but they were divided
on therapeutic cloning. The
majority of the council supports a
moratorium of two to six years on
research cloning, but a few of its
18 members – including some
scientists – have voiced
opposition to such a move.
The council’s chairman,
philosopher Leon Kass of the
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Scientific promise in the therapeutic potential of early embryonic stem
cell research to treat presently intractable diseases is still meeting
ethical, regulatory and patent challenges. Nigel Williams reports on
recent moves in Europe and the US.
High hopes: Researchers continue to look at a variety of sources
of potential stem cells given the ethical issues surrounding the
use of embryo-derived cells for human treatments. Bone marrow
cells, shown here, have been one source for such cells but many
researchers believe embryo-derived cells hold most promise.
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University of Chicago, said that
the panel’s report, expected to be
published this summer, will
probably include a majority
verdict and some dissenting
views. ‘When he made his
decision on stem cells, the
president got as much
information as he could,’ Kass
said. ‘I don’t think we’ll do him a
service if we don’t make as
strong a case as possible for the
different sides of the debate’, he
believes.
In the Senate, there also seems to
have been some change in attitude.
Sam Brownback (Republican,
Kansas) leads opposition to
therapeutic cloning. But he
announced last month that he was
abandoning his efforts to persuade
the Senate to pass a bill outlawing
such research. He says he will now
work to win congressional approval
for a two-year moratorium on such
work.
Meanwhile, efforts to discover
potentially therapeutic stem cells
from sources other than early
embryos, which most people
would find ethically preferable,
continue to throw up tantalising
results that suggest there may be
alternatives to work with embryos.
Recently, Nature reported work by
a team led by Catherine Verfaillie
at the University of Minnesota,
which reported the growth of
stem-like cells from mesenchymal
cells derived from the bone
marrow of mice, rats and humans.
But many scientists remain
sceptical about the therapeutic
potential of some of the studies
with cells derived from older
animals. 
While politicians argue about
the public stand on embryonic
stem cells, the first patent to
cover human cloning has been
approved by the US Patent and
Trademark Office. The patent was
granted in April last year but its
existence has only recently been
discovered.
Patent Watch, the interest
group that made the discovery,
said the patent is registered to the
University of Wisconsin, with
financial interest shared by the
private company Biotransplant in
Massachusetts. 
The patent covers a ‘method of
producing a cloned mammal’ and
even refers specifically to the use
of human embryo cells. Unless the
term ‘non-human’ is added, any
phrase in a patent containing the
word ‘animal’ or ‘mammal’
encompasses humans.
Unlike Europe, where the
European Patent Office has put a
ban on patents involving human
cloning, there are no regulations
prohibiting such patents in the US.
‘This is not a slippery slope, rather
this is an ethical and legal free fall,’
says Patent Watch executive
director Andrew Kimbrell.
The European Union is also
grappling with the issue of stem
cells and potential therapeutic
cloning. It has just published a
report of a major meeting it
recently held in Brussels attended
by researchers, representatives of
patient groups and members of
the public in an effort to gather
views to help develop EU policies.
Ann McLaren, a developmental
biologist from Cambridge, UK, told
the meeting: ‘In the US, publicly
funded research on stem cells is
restricted so much that the quality
of the science is threatened,
whereas industry funded research
is not regulated at all with little or
no ethical overview. I’d like to
think we could do better in
Europe.’
The meeting heard about the
keenness from researchers and
patients that stem cell work
should go ahead. ‘Patients are
crying out for cell therapies…
although the current ethical
discussions are important, they
may become less so if there are
some real successes, as we saw
with in vitro fertilization,’ biologist
Martin Raff, of University College
London, said.
Peter Gruss, head of the Max
Planck Society in Germany said:
‘The problem here is that both
action and inaction have serious
consequences, either for the
embryo or for patients who are
suffering and who might be
helped by embryonic stem cell-
based therapy.’
But the meeting was
introduced by a Spanish multiple
sclerosis patient, Jose-Maria Villa
Valverde. ‘I have multiple
sclerosis, but this also concerns
Parkinson’s disease, leukaemia
and cancers...  I don’t think that
for these people the ethical
debate has any meaning. They
just don’t see. What they urgently
need is a solution and at the
moment the solution lies in stem
cells.’ 
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Focus of attention: An eight-cell stage
human embryo. Cells from early embryos
continue to be a key source for therapy
research. (Science Photo Library).
